Publications
Yedle R, Reniguntla MK, Puttaswamy R, Puttarangappa P, Hiremath S, Nanjundappa M, Jayaraman R. 2023. Neutropenic Rat Thigh Infection Model for Evaluation of the Pharmacokinetics/Pharmacodynamics of Anti-Infectives. Microbiol Spectrum e0013323. doi: 10.1128/spectrum.00133-23.
Reniguntla MK, Yedle R, Puttaswamy R, Puttarangappa P, Hiremath S, Pawar A, Nanjundappa M, Jayaraman R. 2020 Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice. Curr Drug Metab. 21(2) :132-139.
Hameed P S, Bharatham N, Katagihallimath N, Sharma S, Nandishaiah R, Shanbhag AP, Thomas T, Narjari R, Sarma M, Bhowmik P, Amar P, Ravishankar R, Jayaraman R, Muthan K, Subbiah R, Ramachandran V, Balasubramanian V, Datta S. 2018 Nitrothiophene carboxamides, a novel narrow spectrum antibacterial series: Mechanism of action and Efficacy. Sci Rep. 8;8(1):7263. doi: 10.1038/s41598-018-25407-7.
Kulkarni A, Caporali P, Dolas A, Johny S, Goyal S, Dragotto J, Macone A, Jayaraman R, Fiorenza MT. 2018. Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder. Sci Rep. 22; 8(1):9547. doi: 10.1038/s41598-018-27926-9.
Jayaraman R, Pasha MK, Williams A, Goh KC, Ethirajulu K. 2015. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans. Drug Metab Lett. Jan 18. [Epub ahead of print]
Hart S, Novotny-Diermayr V, Goh KC, Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, Nagaraj H, Jayaraman R, Pasha KM, Ethirajulu K, Chng WJ, Mustafa N, Goh BC, Benes C, McDermott U, Garnett M, Dymock B, Wood JM. 2013. VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer. Mol Cancer Ther. 12(2):151-61.
Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. 2012. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 30(33):4161-7.
Madan B, Goh KC, Hart S, William AD, Jayaraman R, Ethirajulu K, Dymock BW, Wood JM. 2012. SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J Immunol. 189(8):4123-34.
Novotny-Diermayr V, Hart S, Goh KC, Cheong A, Ong LC, Hentze H, Pasha MK, Jayaraman R, Ethirajulu K, Wood JM. 2012. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2(5):e69. doi: 10.1038/bcj.2012.14.
Pasha MK, Jayaraman R, Reddy VP, Yeo P, Goh E, Williams A, Goh KC, Kantharaj E. 2012 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 6(1):33-42.
William AD, Lee AC, Poulsen A, Goh KC, Madan B, Hart S, Tan E, Wang H, Nagaraj H, Chen D, Lee CP, Sun ET, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. 2012. Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis. J Med Chem. 55(6):2623-40
William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M, Sun ET, Hu C, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. 2012. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem. 55(1):169-96.
Jayaraman R, Pilla Reddy V, Pasha MK, Wang H, Sangthongpitag K, Yeo P, Hu CY, Wu X, Xin L, Goh E, New LS, Ethirajulu K. 2011. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. Dec; 39(12):2219-32.
Ethirajulu Kantharaj and Ramesh Jayaraman. 2011. Histone deacetylase inhibitors as therapeutic agents for cancer therapy: Drug Metabolism and pharmacokinetic properties. Chapter 5 "Drug Development - A Case Study Based Insight into Modern Strategies", book edited by Chris Rundfeldt, ISBN 978-953-307-257-9, Published: December 7, 2011 under CC BY 3.0 license
KC Goh, V Novotny-Diermayr, S Hart, LC Ong, YK Loh, A Cheong, YC Tan, C Hu,
R Jayaraman, AD William, ET Sun, BW Dymock, KH Ong, K Ethirajulu, F Burrows and JM Wood. 2011. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties Leukemia. 26(2):236-43
R Jayaraman, AD William, ET Sun, BW Dymock, KH Ong, K Ethirajulu, F Burrows and JM Wood. 2011. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties Leukemia. 26(2):236-43
William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET, Goh KC, Ong WC, Goh SK, Hart S, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW. 2011. Discovery of the Macrocycle SB1518, a Potent JAK2/FLT3 Inhibitor for the Treatment of Myelofibrosis and Lymphoma. J Med Chem. 2011 Jul 14; 54(13):4638-4658. [Certified by ACS as the highly quoted paper in J Med Chem for 2011].
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW. 2011. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 25(11):1751-9
Novotny-Diermayr V, Sausgruber N, Loh YK, Pasha MK, Jayaraman R, Hentze H, Yong WP, Goh BC, Toh HC, Ethirajulu K, Zhu J, Wood JM 2011. Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue. Mol Cancer Ther. 10(7):1207-17
Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents and Chemother. 51(2): 576-582
Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Kantharaj E, Balasubramanian V. 2004 Isoniazid Pharmacokinetics-Pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents and Chemother. 48(8): 2951-2957
Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003 Pharmacokinetics-Pharmacodynamics of rifampicin in an aerosol infection model of tuberculosis, Antimicrob. Agents and Chemother. 47(7):2118-24.
Usha V, Jayaraman R, Toro JC, Hoffner SE, Das KS. 2002. Glycine and alanine dehydrogenase activities are catalyzed by the same protein in Mycobacterium smegmatis: upregulation of both activities under microaerophilic adaptation, Can. J.Microb. 48(1):7-13